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One of the main goals of materials science in the 21st century is the development of materials with
rationally designed properties as substitutes for traditional pharmacotherapies. At the same time,
there is a lack of understanding of the exact material properties that induce therapeutic effects in
biological systems, which limits their rational optimization for the related medical applications. This
study sets the foundation for a general approach for elucidating nanoparticle properties as determi-
nants of antibacterial activity, with a particular focus on calcium phosphate nanoparticles. To that
end, nine physicochemical effects were studied and a number of them were refuted, thus putting an
end to frequently erred hypotheses in the literature. Rather than having one key particle property
responsible for eliciting the antibacterial effect, a complex synergy of factors is shown to be at
work, including (a) nanoscopic size; (b) elevated intracellular free calcium levels due to nanoparti-
cle solubility; (c) diffusivity and favorable electrostatic properties of the nanoparticle surface, pri-
marily low net charge and high charge density; and (d) the dynamics of perpetual exchange of
ultraﬁne clusters across the particle/solution interface. On the positive side, this multifaceted mecha-
nism is less prone to induce bacterial resistance to the therapy and can be a gateway to the sphere of
personalized medicine. On a more problematic side, it implies a less intense effect compared to
single-target molecular therapies and a difﬁculty of elucidating the exact mechanisms of action,
while also making the rational design of theirs for this type of medical application a
challenge.
I. INTRODUCTION
The unceasing coevolution of the microbiota and complex
organisms requires constant innovation in the domain of
strategies and forms by which pathological bacterial growths
are kept in check. One of the essential goals for biomaterials
science in the new millennium is to discover materials that
could either replace the traditional, small-molecule antibiot-
ics or act in synergy that boosts the activity of weak or inef-
fective antibiotics. Traditional antibiotics are notorious for
their promotion of microbial resistance, low targeting poten-
tial, and an array of systemic side effects, which are all
issues amendable with the use of appropriate materials
science platforms. In the ﬁrst part of this study,1 we reported
on an intriguing antibacterial effect caused by calcium ortho-
phosphate (CP) nanoparticles, including hydroxyapatite
(HAp) and amorphous CP (ACP). The nanoparticles were
not only effective against both lab strains and clinical isolates
when delivered alone, but were also able to synergize with
a number of different antibiotics and signiﬁcantly increase
their activity against a variety of pathogenic and opportu-
nistic bacteria, including some of the strains that are
insensitive to antibiotics per se. The nanoparticles also
exhibited a selective response whose origin was unclear:
namely, while HAp was more effective than ACP against
Gram-negative species and drug-resistant strains, it was not
effective against Gram-positive strains, against which ACP
was very effective.1
HAp is the most sparsely soluble nondoped CP phase and
is also the mineral component of all hard tissues in the body
except for the minor calcite portions of the middle ear.
In contrast, ACP has been detected as the solid intermediate
in the crystallization of both biogenic and synthetic HAp,
forming as the result of the Ostwald law of stages, which
predicts the successive formation of phases in the order of
their stability. Because of its metastability, it transforms after
prolonged contact with a supernatant to either HAp or dical-
cium phosphate (DCP), depending on whether the terminal
pH is higher or lower than ∼6.8, respectively. Mammalian
blood is supersaturated with respect to Hap, and the ACP
units in it constantly form and dissipate, with the role in pre-
venting their crystallization into HAp being played by α2-HS
glycoprotein/fetuin-A and other serum proteins that shield
individual ACP nanoparticles and prevent their aggregational
growth,2 posing along the way an intricate question of
whether these omnipresent ACP units in circulation play an
immune role undiscovered before. One such immune role
was ascribed to Mg-enriched ACP nanoparticles forming in
the ileum due to endogenous secretion of calcium and phos-
phate ions from the distal small intestine to the lumen, where
they trap orally entered antigens and bacterial peptidoglycans
and chaperone them to the immune cells of the intestinal
tissue for immunosurveillance.3,4 Being less stable and more
chemically active than HAp, ACP has been used in some
dental formulations to remineralize enamel,5 while binding
with high afﬁnity to S. mutans6 and exhibiting mild anticar-
iogenic properties whose origins are yet to be elucidated.
Most of these formulations apply ACP in combination with
casein phosphopeptides, providing for a rudimentary
mimicry of sophisticatedly structured casein micelles stabi-
lized in milk by ∼2 nm sized ACP nanoparticles lying along
the internal micelle membrane.7 However, despite their pros-
pect as caries-preventing additives in toothpastes and food,8
the only metastudy of clinical trials of these formulations
performed to date concluded that there was an insufﬁcient
evidence to justify the recommendation for their use in pre-
vention of caries in vivo.9 This impasse faced by CP nano-
particles as potential antimicrobials is largely due to the
virtual nonexistence of studies focused on understanding
their mechanism of action (MoA).
In this follow-up to the ﬁrst part of the study, we shift our
focus from the effect to its causes, believing that understand-
ing the MoA of CP nanoparticles is a prerequisite for the
rational optimization of their properties for an antibacterial
response comparable in magnitude to today’s gold standards
in the domain of inorganic antimicrobials, namely, silver
and, to some extent, gold, zinc, copper, and their com-
pounds. In this attempt to decipher the MoA, we compare
three stoichiometrically distinct CP nanopowders, including
HAp, ACP and, to some extent, DCP. We compare them not
so much to assess their individual antimicrobial potencies as
to derive compositional parameters decisive in deﬁning
the MoA.
In our planning for this study, we evoked a number of
testable hypotheses explaining the MoA of CP nanoparticles.
One hypothesis invoked to explain the antibacterial proper-
ties of these complexes refers to their ability to adhere to
dental bioﬁlm, interfere with the binding capacity of the bac-
teria,10 and also induce high intracellular free calcium ion
concentrations.11 Another possibility is that hydroxylated CP
nanoparticles, such as HAp and some ACPs, act in a merely
bacteriostatic fashion, thanks to their “smart” solubility in
direct proportion with the acidity of the medium12 and acid-
neutralization capacity,13 thus restricting the conditions for
the growth of bacteria, including S. mutans and S. aureus,
which favor mildly acidic conditions over the physiological
ones.14,15 Multiple other possibilities could be proposed,
including the disruptive cell membrane effect of CP nanopar-
ticles or Posner’s clusters,16 9 Å sized, heavily hydrated, and
nonequilibrium CP units forming the building blocks of CP
nuclei and presumably constantly separating from and reinte-
grating with the CP surface in an aqueous medium. The for-
mation of reactive oxygen species owing to the defective and
semiconducting CP structure, as in analogy with the effect
attributed to metal oxide nanoparticles constitutes another
potential MoA. Therefore, in what follows, we hypothesize
on a number of possible particle properties responsible for
the observed antibacterial effect of CP nanoparticles and
investigate them one by one. The goal of this methodology
is to discern the properties of the materials responsible for
eliciting the antibacterial effect, to which end it is analogous
to digging a tunnel through a black box by starting from its
materials science side. The results in this report will be even-
tually tied to its follow-up, the third and the ﬁnal report of
this study, which will attempt to distinguish the molecular
targets in the bacterial cell vulnerable to the action of CP
nanoparticles. This third and ﬁnal report will be analogous to
digging a tunnel through the aforementioned black box by
starting from its cell biology side. The hope underlying this
quest for revealing the true MoA of CP nanoparticles is that
these two burrows will meet in the middle, yielding a single
and consistent model connecting material properties with
their biological effects.
To sum up, here we report on our effort to understand
which properties of CP nanoparticles play a key role in
causing this antibacterial effect by bringing three fundamen-
tally different CP nanopowders and cements into interaction
with different bacterial strains and following the bacterial
response at different levels, using a range of chemical and
biological assays. Better understanding of the fundamental
principles underlying the antimicrobial activity of CP nano-
particles, including their MoA, is expected to be helpful in
the further optimization of these nanoparticle properties and
in the design of inorganic nanoparticle alternatives to small-
molecule antibiotics in the global effort to curb the rising
resistance of bacterial pathogens to existing therapies.
II. MATERIALS AND METHODS
A. Synthesis
Raw CP powders of different monophasic compositions
were prepared as described in detail in the ﬁrst part of this
study.1 Brieﬂy, HAp [Ca5(PO4)3OH] was synthesized by
adding an aqueous solution containing 0.06 M NH4H2PO4
and 1.75 vol. % NH4OH dropwise to the same volume
of an aqueous solution containing 0.1 M Ca(NO3)2 and
3.5 vol. % NH4OH heated to 60–80 °C, bringing the sus-
pension to boil, aging for 24 h, washing with water and
separating the precipitate by centrifugation at 3500 rpm,
and drying in air. DCP (CaHPO4) was synthesized by
following the same procedure except for using 0.33 M
Ca(NO3)2 as the calcium solution and 0.25 M NH4H2PO4
containing 0.05 vol. % NH4OH as the phosphate solution
and not bringing the suspension to boil. ACP was synthe-
sized by abruptly adding a solution containing 0.5 M
Ca(NO3)2 and 2 vol. % NH4OH into the same volume of
a solution containing 0.2 M NH4H2PO4 and 1 vol. %
NH4OH, washing the precipitate ﬁrst with 0.14 vol. %
NH4OH, then with ethanol, drying in air, and storing at
4 °C to prevent spontaneous transformation to HAp. ACP
and HAp cements were prepared by mixing 10 mg of the
corresponding dry powders with 15 μl Na2HPO4, homoge-
nizing the mixture manually and immediately depositing it
either onto agar plates or into bacterial broths.
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B. Physicochemical characterization
Zeta potential and hydrodynamic diameters of particles in
suspension were measured in a dip cell using a Zetasizer
Nano-ZS (Malvern) dynamic light scattering device. To
create ξ-potential versus pH curves, titration with 1M HCl
proceeded from the physiological pH to higher pH values
with one sample and from the physiological pH to lower pH
values with another identical sample. The morphology of the
CP nanopowders was analyzed on a Hitachi S-4300SE/N
scanning electron microscope (SEM) at the Lawrence
Berkeley National Lab, with the electron beam energy of
15 kV. Particle size distribution histograms for the different
types of cements and HAP precursors were obtained from
scanning electron micrographs using IMAGEJ (NIH, Bethesda,
MD) and the sample size of 200–1000 particles. X-ray dif-
fraction (XRD) studies were carried out on a Siemens D500
diffractometer using CuKα = 1.5418Å as the wavelength of
the radiation source, the step size of 0.04°, and 1 s of sample
irradiation time per step. The UV–Vis diffuse reﬂectance
spectra were collected in the 200–800 nm wavelength range
on an Agilent Cary 5000 spectrophotometer equipped with a
diffuse reﬂectance accessory. Photoluminescence (PL) spectra
were recorded on a Horiba Jobin Yvon Fluorolog FL3–22
spectroﬂuorometer using Xe lamp excitation with the wave-
length of 325 nm. Luminescence photographs of ACP and
HAp under the 405 nm wavelength irradiation in dark were
taken by a digital camera.
C. Calcium assays
Calcium release analyses were done by immersing 10 mg
of powders in 10 ml of 20 mM Bis-Tris aqueous solution
(pH 6.8) and measuring the solution potential using the Ca2+
microelectrode in combination with a reference electrode
(Microelectrodes, Inc.) on an Accumet pH-meter (Fisher
Scientiﬁc). Calibration solutions were prepared in the same
solvent using CaCl2 in the 1 μM–100 mM concentration
range. Calibration data points were exponentially ﬁtted in the
1 μM–1 mM CaCl2 (OriginPro 2016), and the numerical ﬁt
was used to convert the electrode potential readings into free
Ca2+ molar concentrations. All the samples were analyzed
in triplicates and compared against the control samples.
Free intracellular Ca2+ concentrations were measured using
Fura-2 assay and a modiﬁed version of an older protocol.
For that purpose, the overnight cultures of E. coli treated
with 60 mg/ml of either ACP or HAp nanoparticles ﬁrst had
the particles dissolved by centrifuging 200 μl of the suspen-
sion and resuspending in 200 μl of 110 mM solution of NaCl
in 250 mM HCl. After the particles were removed, the pH
was brought back to neutral by centrifuging and suspending
in buffer A. The bacteria were then permeabilized to Fura-2
dye by resuspending in 0.12M Tris-HCl (pH 8) solution
containing 200 μM EDTA at 37 °C for 2 min and adding
MgCl2 to the ﬁnal concentration of 1 mM to stop the reaction,
after which the bacteria were centrifuged and washed once
with buffer A. After permeabilization, bacteria were incubated
in 5 μM Fura-2 pentaacetoxymethyl ester in buffer A at 37 °C
for 2 h, after which the volume of the suspension was
increased by adding 25 times more buffer A, centrifuging and
washing 3× with buffer A. Suspensions were excited at 340
nm, and the emission was measured at 510 nm. Increased
intracellular free calcium ion concentration, [Ca2+]i, corre-
sponds to a higher emission under the 340 nm excitation com-
pared to the control and the following equation was used to
convert the ﬂuorescence at 510 nm, F, in the CP-treated
samples to [Ca2+]i:
[Ca2 þ ]i ¼ Kd  (F–Fmin)=(Fmax–F): (1)
The value of 225 nM was taken for the dissociation constant
for Fura-2, Kd.
17 The bacterial cell control permeabilized with
25 μM gramicidin was used to measure Fmax, and the bacterial
cell control incubated with Ca2+-chelating agent, 10 mM ethyl-
ene glycol tetraacetic acid, was used to measure Fmin.
D. Antibacterial assays
Antibacterial assays performed by dispersing nanoparti-
cles in Luria broths (LB) and by depositing them on LB agar
plates were described in the ﬁrst part of the study.1 Brieﬂy,
1 ml of 1:50 diluted overnight cultures of bacteria mixed
with CP nanopowders were incubated overnight at 37 °C and
200 rpm, with or without the presence of concomitantly
added antibiotics. After the overnight incubation, 200 μl of
the bacterial suspension was centrifuged at 10 000 rpm and
resuspended in 200 μl of 110 mM solution of NaCl in
250 mM HCl (150 μl 0.85 wt. % mixed with 50 μl of 1 M
HCl) to dissolve the CP nanoparticles and avoid their inter-
ference with the optical density readings. All experimental
sample groups and controls were subjected to centrifugation
and HCl treatments. In the agar diffusion antibacterial
assays, 5 mg of CP nanopowders were placed onto a
bacterium-infused LB agar plate with the spot radius of
1 cm. The agar plates were incubated for 24 h at 37 °C, after
which the radius of the zone of inhibition was used to gauge
the antibacterial activity of the cements. All the samples for
both antibacterial assays were analyzed in triplicates.
Experiments involving concomitant UV irradiation of broths
with and without the ACP powder were performed by
placing 1 ml of control broths or broths containing 90 mg/ml
ACP into Shimadzu Q71483 UV/Vis spectrophotometer and
irradiating for 5 min with the laser light wavelength of
220 nm, after which they were aged overnight on the shaker at
37 °C and had optical densities at 600 nm, indicative of the
bacterial viability, measured (BMG LABTECH FLUOstar
Omega) and converted to the number of colony forming units
(CFU) by multiplying with 8 × 108.
E. Drug loading and release
The concentrations of vancomycin, erythromycin, and
ampicillin loaded onto CP particles and released after 24 h
was determined by creating a standard curve of agar
plate inhibition zones versus antibiotic concentration in the
0.075–20 mg/ml range and then comparing it with the zone
created by a given amount of antibiotic-loaded CP particles.
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Binding of E. coli derived lipopolysaccharide (LPS, VWR)
onto CP nanoparticles was determined by incubating 5mg/ml
HAp or ACP nanoparticles in 40mg/ml LPS solutions in
water and measuring the optical density at 280 nm after 1 h
and also taking the FTIR spectra of the corresponding precipi-
tate obtained following centrifugation. LPS loading efﬁciency,
x, was deﬁned as
x ¼ m(LPS)=m(CP)  100%, (2)
where m(LPS) is the mass of LPS bound onto CP and m(CP) is
the mass of CP. LPS binding, y, efﬁciency was deﬁned as
y ¼ m(LPS)=mT(LPS)  100%, (3)
where m(LPS) is the mass of LPS bound onto CP and mT(LPS)
is the total mass of LPS.
III. RESULTS AND DISCUSSION
In the effort to delineate the key structural effects respon-
sible for the antibacterial properties of CPs, nanoparticles of
three chemically and crystallographically different CP phases
were compared: (i) hydroxylated HAp, the CP phase com-
prising the mineral component of mammalian bone tissues;
(ii) hydrogenated DCP, a CP phase forming in acidic solu-
tions and strictly found in pathogenic calciﬁed tissues; and
(iii) ACP, a phase that is highly active, metastable, and quick
to transition to HAp, acting as is its precursor in the process
of biomineralization. Figure 1 displays SEM micrographs
and x-ray diffractograms of HAp and ACP, the two main
nanomaterials used in this study, demonstrating high levels
of morphological similarity, but different crystallinities.
Their more detailed physicochemical characterization, such
as particle size, morphology, crystallinity, phase composi-
tion, and thermal stability, including the basic information
about their antibacterial efﬁcacy and selectivity, was given in
the ﬁrst part of this study.1
This section follows an innovative, but logical form by
being divided to nine subsections, each dealing with the
investigation of a single effect potentially causative of the
observed antibacterial activity and ending up with an estimate
of how realistic and/or critical its role in the process is. This
approach is justiﬁed by the fact that will become obvious in
the course of the discussion: rather than a single particle prop-
erty being the determinant of the antibacterial effect, a number
of them acting in synergy are responsible for causing this
effect. The ﬁndings resulting from the approach based on ana-
lyzing the effects of one variable at a time are limited by the
fact that these different variables cannot be fully disentangled
from one another. For example, with changes in crystallinity,
the surface composition, the structural water content, faceting,
and diffusivity all change as well, even when the particle size
and shape, as is the case here, are maintained constant.
Likewise, in the attempt to modify the surface defect concen-
tration using a high-temperature treatment, both crystallinity
and the surface ion/cluster exchange dynamics across the parti-
cle/solution interface are modiﬁed too. Also, with an increase
in the particle size, the surface curvature and, thus, the interfa-
cial free energy change as well, affecting an array of properties
directly or indirectly dependent on it. Notwithstanding this
fundamental limitation, one such discernment of possible
factors and their analysis are carried out with the expectation
that they will present the basis for the future optimization and
design of CP nanoparticles for the exhibition of a maximal
antibacterial activity against medically relevant pathogens.
A. Calcium ion release
The antibacterial activity of silver nanoparticles is usually
attributed to their intracellular dissolution and release of Ag+
ions that inhibit DNA replication and inactivate ribosomal
subunit proteins and enzymes involved in respiration and
adenosine triphosphate (ATP) production.18–20 It is tempting
to imagine that CPs share a similar MoA. Accordingly, Ca2+
ions released by the CP particles would have the ability of
eliciting a toxic effect on the bacterial cells, similarly to the
mechanism that they have been hypothesized to owe their
FIG. 1. SEM images and XRD patterns of ACP (a) and HAp (b) nanoparticles. Diffraction peaks labeled with • originate from HAp.
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capacity to deteriorate the eukaryotic cells to.21,22 Hence, our
initial hypothesis was that the discrepancy between the high
activity of ACP and the low activity of HAp against S.
aureus reported in the ﬁrst part of this study1 may be
explained by the higher solubility of ACP (0.8 g/ml) in phys-
iological media than that of HAp (0.3 g/ml)23 and the conse-
quently more copious release of Ca2+ ions by ACP than by
HAp. In support of this hypothesis, we recalled that carboxylic
moieties of peptidoglycans and polyphosphate groups of tei-
choic acid (TA) comprising the cell wall of Gram-positive bac-
teria provide the binding sites for Ca2+ and other metal ions.24
Earlier research showed that Ca2+ ions delivered as CaCl2 salt
had a deadly effect on S. aureus at ≤40mM by promoting
Ca2+-cardiolipin binding and decreasing the membrane curva-
ture, thus destabilizing and eventually destroying it.25 Per this
research, this effect was absent in E. coli and B. subtilis, pre-
sumably because of the thinner proteoglycan cell membrane
layer and the double cell wall in the latter. If realistic, this sus-
ceptibility of TA toward inactivation by Ca2+ ions would also
explain the efﬁcacy with which Ca(OH)2 particles, relying
mostly on Ca2+ ions to elicit the antibacterial effect, are used
as endodontic medicaments in dentistry.26 It might also
explain why bacteremic patients are diagnosable with hypocal-
cemia in particular clinical circumstances,27 a possible result
of the recruitment of Ca2+ ions from the serum to the site of
infection to assist in neutralization of the pathogenic cells.
To test whether ionic calcium is the “culprit,” the antibac-
terial effect of sole Ca2+ ions in concentrations equivalent to
those released by CP nanoparticles in PBS was measured on
S. aureus and P. aeruginosa. Based on the current solubility
analyses [Figs. 2(a) and 2(b)], agreeing with the previous
ones,28 the 10–100 mg/ml range for ACP corresponded to
4–40 mM of Ca2+ concentration range using a water-soluble
calcium salt, CaCl2. However, no parallel decreases in viability
FIG. 2. Time-dependent release of free calcium ions due to dissolution of different CP phases at 1 mg/ml (a) and solubility in a solution equilibrated after
aging the precipitate for 3 h (b). Data points represent averages (n = 3) and error bars represent the standard deviation. Comparison of P. aeruginosa (c) and
S. aureus (d) viabilities in the 4–40 mM range of CaCl2 and in the 10–100 mg/ml range of ACP. Data points represent averages (n = 4) and error bars represent
the standard deviation. Arrows in (c) and (d) denote abscissas that the individual curves correspond to.
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of populations treated with comparable concentrations of ACP
and CaCl2 were noticed for either of the two bacterial species
tested [Figs. 2(c) and 2(d)]. As a matter of fact, the viability of
both types of bacteria increased as the free Ca2+ concentration
went up. Moreover, the viability of broths treated with the
nanoparticles was consistently lower than that of the broths
challenged with the comparable levels of free Ca2+ ions. This
has proven that Ca2+ ions per se cannot be the sole bearer of
the antibacterial activity of CPs. Though their effect cannot be
discarded with certainty, at best it is delivered in synergy with
one or more CP particle properties. Higher concentrations of
calcium released in the ionic form upon the treatment with
ACP might destabilize the cell wall and make the cell suscepti-
ble to a complementary antibacterial effect delivered by the
particles. Their ability to open up the mechanosensitive ion
channels and facilitate the intracellular delivery of the nanopar-
ticles is also a possibility.
Another possibility is that the uptake and intracellular
degradation of particles increases free calcium levels beyond
those resulting from the rather sparse dissolution in regular
media. E. coli is capable of maintaining [Ca2+]i homeostasis
at ∼100 nM even when the extracellular levels exceed
10 mM,29 but if internalized and degraded intracellularly, CP
particles could theoretically ﬂood the cell with Ca2+ and
induce damage to it. To test if the uptake of the particles and
their intracellular dissolution is the mechanism for increasing
[Ca2+]i to toxic levels, Fura-2 analysis was performed on
E. coli challenged with 60 mg/ml ACP or HAp. At this dose,
which exceeded the IC50 value for HAp and equaled that of
ACP, [Ca2+]i increased twofold, from 111.5 ± 9.4 nM in the
control E. coli to 215.7 ± 9.9 nM inside ACP-challenged
E. coli and 248.3 ± 18.3 nM inside HAp-challenged E. coli
(Fig. 3). ACP is more soluble than HAp and two effects
are at work that explain the somewhat higher [Ca2+]i in
HAp-treated E. coli: (1) ACP comprises 22.2 wt. % of lattice
water as opposed to only 6.6 wt. % for HAp (Ref. 1) and (2)
the 60 mg/ml CP dose is equal to the IC50 of ACP, but twice
higher than the IC50 of HAp. Also, countering the expecta-
tions, there is evidence that ACP can be stabilized intracellu-
larly, presumably due to the high concentration of Mg2+ ions
and ATP,30 rather than swiftly transforming to HAp or dis-
solving in the digestive compartments of the cell. All these
arguments imply a higher potential for cytosolic leakage and
CP/Ca2+ entrance into the cell in HAp-treated bacteria than in
ACP-treated ones. Still, although higher than the control, the
intracellular Ca2+ levels were within the range of resting cyto-
solic [Ca2+]i of E. coli, which can tolerate [Ca
2+]i peaks reach-
ing 1–5 μM.31 Therefore, the increased level of intracellular
ionic calcium may destabilize the bacteria and make them sus-
ceptible for the action of other factors, but it, itself, cannot be
responsible for the elicitation of the antibacterial effect.
This conclusion is backed by the signiﬁcant difference
observed in the effect of ACP and HAp depending on
whether the bacteria were Gram-positive or Gram-negative,
suggesting that ACP and HAp must have a different MoA.
Such different modes of action were previously ascribed to
nanoparticles with identical compositions, but produced
using different methods, one of which were carbon nanopar-
ticles.32 This difference in the MoA implies that a
particle-related effect must be the key to mechanistically
explaining the activity of CPs, given that the dissolved units
of ACP and HAp would be qualitatively indistinguishable.
Since the toxic inﬂuence of phosphates and hydroxyls, the
other two ionic species in HAp, is also less probable than
those of Ca2+, these have been the ﬁrst out of many indica-
tions that not ions, but particles exhibit properties responsible
for the antibacterial activity. Indirectly, also, the observed
discrepancy between the activities of ACP and HAp is the
ﬁrst indicator of a multifactorial nature of the antibacterial
activity of CP nanoparticles.
B. Surface charge
In contrast to the global surface charge distribution, elec-
trodynamic characteristics of the double charge layer of ACP
and HAp are expected to be very different. A comparative
analysis of ξ-potential as a function of pH for ACP and HAp
showed that the ξ-potentials at the physiological pH were
negative for both materials, but their absolute values were
higher for HAp than for ACP: −12.5 versus −9 mV, respec-
tively. Interestingly, HAp is more receptive to negatively
charged ions in its double layer, allowing for the ξ-potential
to drop to more negative values in the alkaline pH range
than ACP, while ACP is more receptive to positively charged
ions in its double layer, allowing for the ξ-potential to enter
the positive value range under the acidic conditions
[Fig. 4(a)]. Speciﬁcally, in the entire pH range between the
point of zero charge (PZC) at 5.75 and the onset of dissolu-
tion at pH 3–4, the ξ-potential of HAp is positive, but does
not increase above 0.2 mV, whereas that of ACP exceeds 4 at
pH 4.9.
FIG. 3. Intracellular free Ca2+ concentration in control E. coli populations
and populations challenged with 60 mg/ml ACP or HAp measured using the
Fura-2 assay. Data points represent averages (n = 3) and error bars represent
the standard deviation. Data points statistically signiﬁcantly lower (p < 0.05)
compared to other data points are marked with an asterisk. Data points statis-
tically insigniﬁcantly different (p > 0.05) compared to other data points are
marked with “n.s.”
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The gradual dissolution of both materials begins at
pH < 4.0, at which point the ξ-potential abruptly drops to
values lower than −10 mV, intensely negative despite the
excess of protons in the medium. This effect is expected to
be the result of the selective dissolution favoring the release
of lighter, cationic Ca2+ before the degradation and dissipa-
tion of the network of heavier phosphate ions. The same
atomic weight argument can be used to explain a similar
excess of phosphate ions in the solid phase during the earli-
est stages of nucleation and crystal growth33 as well as the
fact that the formation of HAp from amorphous precursors is
correlated to the activity coefﬁcient and speciation of the
phosphate ion.34
In theory, the moderate negative charge of both ACP and
HAp nanoparticle surfaces under the physiological condi-
tions may allow for the electrostatic attraction of the nanopar-
ticles to the peptidoglycan layer rich in cationic alanine and
lysine residues surrounding the cell wall of Gram-positive
bacteria and to the core polysaccharides sticking out of the
outer membrane of Gram-negative bacteria, rich in different
cationic species, i.e., 4-aminoarabonises and phosphoetha-
nolamines.35 If this was correct, however, then the different
modes of action of ACP and HAp, such as those presented in
Fig. 4(b), could not be explained on the basis of surface
charge effects and the relevancy of this parameter would
have to be excluded ab absurdum.
A more plausible scenario where surface charge would
have some antibacterial effect involves electrostatic repulsion,
not attraction. Namely, with the electrostatic repulsion barrier
being the ﬁrst one that must be crossed by a nanoparticle
en route to the bacterial cell surface, the somewhat lower
surface charge of ACP might favor the interaction with the
cell wall over HAp. Presumably caused by a higher content of
adsorbed and lattice water in ACP than in HAp, this lower
surface charge may also facilitate the transport of the nanopar-
ticle across the cell membrane, as in gene delivery, alongside
acting as its potential disruptor, thus explaining the discrep-
ancy between the antibacterial activity of these two forms of
CP. One thing that is not clear is whether the relatively small
difference in the ξ-potential at this pH, amounting to only
3–4mV, is sufﬁcient to justify the expectation of a more
intense hydrophobic barrier permeation propensity of ACP.
When it comes to the propensity to traverse or adhere to
the biological barriers, including the cell wall and plasma
membrane, negative surface charge is a hindrance, especially
against phospholipid bilayers inherently incompatible with
the hydrophilic nature of CPs, comprising two relatively
highly charged ionic species: divalent calcium and trivalent
phosphate. Although cationic surfaces tend to have more pro-
nounced antibacterial properties,36 combining cationic and
anionic species on the surface, such as those present on the
surface of CP, can retain the antibacterial efﬁcacy while
regaining better tissue compatibility,37 and this duality is
exactly the strength of CPs. Zwitterionic surfaces, in fact, are
known for their excellent antifouling properties, which they
owe to the tight hydration shells formed around charged
groups.38 Water within this shell has a greater resemblance
to free water than hydrogen-bonded water around simply
hydrophilic groups, such as those of poly(ethylene) glycol
(PEG), and its structuring during the penetration of a foulant
is even less entropically favorable than that around PEG, the
epitome of an excipient for reduced opsonization. CPs may
similarly owe a portion of their antibacterial activity to the
alternation of relatively highly charged ionic species on an
equally highly hydrated surface. Their activity may be due to
the synergy of a translationally symmetric order of two
species, Ca2+ and HxPO4
x–3, that separately have a signiﬁ-
cantly lesser antibacterial potency. It is widely known that the
FIG. 4. (a) Zeta potential vs pH titration curves for HAp and ACP colloids in the 3.5–12 pH range. Phosphate buffered saline (1x), containing 137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4, was used as the medium. Dissolution range is entered at pH < 4, while PZC stands for the point of zero
charge. Data points represent averages (n = 3) and error bars represent the standard error of the mean (SD/n1/2). (b) Comparative curves showing the reduction
in the concentration of bacterial CFU with the concentration of HAp or ACP in broths for one Gram-negative clinical strain, namely, MDR P. aeruginosa, and
one Gram-positive lab strain, namely, S. aureus.
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antifouling properties of zwitterionic materials most critically
depend on the surface charge distribution,39 and it is conceiv-
able that a different distance between constitutive ions on the
surfaces of ACP and HAp—with the caveat that ACP trans-
forms to HAp after sufﬁcient aging in physiological solutions
and that its surface may structurally bear resemblance to HAp
all the way through—may endow these two materials with
vastly different antibacterial properties and be a key to explain-
ing their different speciﬁcities against particular families of
microorganisms. The translational symmetry of surface fea-
tures often has a more pronounced effect on the biological
response than the features per se40 and whether these distances
between charged species on the surface of CP nanoparticles
could be optimized to provide for a more superior antibacterial
effect is a meaningful question to ask at this point.
To sum up, there are valid arguments in favor of the low
surface charge and its zwitterionic distribution as potential
antibacterial factors. The combination of low net charge and
high charge density is intriguing and may be harnessed to
induce intense interactions with cells. However, a minimal dif-
ference in the ξ-potential versus pH proﬁles and the identical
PZC for both materials, 5.75, suggests similar electrostatic
properties of their surfaces and excludes simple electrostatics
as the key antibacterial factor, lest the difference in the activity
of these two materials remains unexplained. This lateral role
of sheer electrostatics is further supported by the fact that
despite the lower absolute value of the ξ-potential, ACP parti-
cles are markedly more colloidally stable than HAp. This
observation hints at the critical role of surface effects other
than the long-range electrostatic, e.g., the diffusion of ionic
units and clusters in the double charge layer. Although surface
charge may lower the energy barrier for nanoparticles coming
into contact with the cells, expecting that this physical factor
alone is sufﬁcient to induce the antibacterial effect would be
overly simplistic and unrealistic. The electrostatic force is a
nondirectional, long-range force and is but a crude prelude to
ﬁner, albeit weaker forces that govern interactions at the
molecular and nanoscales with higher levels of speciﬁcity.41
C. pH changes
The constantly ongoing process of dissolution and repre-
cipitation on the HAp surface entails constant pH ﬂuctua-
tions in the nanoscopic medium surrounding the particle and
it can be hypothesized that such ﬂuctuations could destabi-
lize microorganisms. Equations (4) and (5) simplistically
describe the pH effects accompanying the dissolution and
reprecipitation of one unit cell of HAp, respectively,
Ca10(PO4)6(OH)2 þ 6H2O! 10Ca2þ þ 6HPO42 þ 8OH,
(4)
10Ca2þ þ 6HPO42 þ 2H2O! Ca10(PO4)6(OH)2 þ 8Hþ:
(5)
Figure 5 shows changes in the pH of deionized water
following immersion of the three different CPs. The most
stable phase was, expectedly, HAp, not exhibiting any signif-
icant dissolution, which would have been entailed by a pH
increase from the neutral level. The solubility of DCP was
dependent on the thermal treatment during the synthesis.
Without the thermal treatment that involved the bringing of
the suspension to boil after precipitation to block the particle
surface, DCP proved to be the most soluble CP phase, exhib-
iting the most intense pH drop, down to 5.17 ± 0.01 after 7 h
of aging. With the thermal treatment, the solubility of DCP
was lesser and this difference between the two forms of DCP
indirectly proves that the pH drop is due to the transforma-
tion of amorphous surface layers to HAp/DCP in water
rather than due to dissolution of DCP. In fact, although DCP
FIG. 5. Absolute (a) and differential, dy/dt (b) change in the pH of the supernatant in a 20 mg/ml dispersion of different CP nanopowders in water at 37 °C
over time. Dashed lines in (a) and (b) denote the neutral pH at 37 °C and the zero change in pH over time, respectively. Full and empty red circles denote data
points for DCP not subjected and subjected to the thermal treatment (bringing of the precipitate to boil), respectively. Data points represent averages (n = 3)
and error bars represent the standard deviation.
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is colloquially known as an acidic form of CP, dissolution of
DCP would exert the same effect on pH as the dissolution of
HAp, albeit less intense, the reason being the alkaline nature
of the released amphoteric HPO4
2− ion (pKa = 7.2) under
neutral conditions (pH 6.8 at 37 °C). pH has to exceed 10 in
order for HPO4
2− ion to be acidic, unlike pH 4.7 for H2PO4
−,
explaining why monocalcium phosphate, Ca(H2PO4)2, is the
only true acidic form of CP. This is why precipitation of
DCP was paralleled by a decrease in the pH, as was the
case of HAp. Because of its metastable structure, the most
unstable CP phase was ACP. It exhibited a drop in the pH,
down to 5.31 after 7 h, which was similar, but somewhat
less intense as that seen for DCP, the reason being the
release of free protons following the capture of OH− groups
into HAp forming as the result of dissolution/reprecipitation
process taking place on the surface of ACP [Eq. (5)]. The
increase of pH in the ACP supernatant from the starting
neutral value to 7.90 ± 0.05 (the ﬁrst time point) almost
immediately as the solid phase was brought into contact
with the solution can be explained either by the apatitic
surface of ACP dissolving ﬁrst and raising pH, before
exposing the Ca3(PO4)2 interior and its subsequent, more
gradual transformation to HAp, or by the initial formation
of octacalcium phosphate (OCP) as an intermediate in the
formation of HAp. Namely, ACP→OCP transformation
would lead to the release of six hydroxyl groups from the
solution per the unit cell of OCP [Eq. (6)]. Per Eq. (7), the
subsequent transformation of OCP to HAp would produce a
steeper drop in pH than that excepted from direct ACP→
HAp transition [Eq. (8)], i.e., 1.5 protons vs 0.667 protons
per the stoichiometric unit of HAp, respectively. The differ-
ential curves demonstrate the largest degree of pH change
occurring in the solution interfaced with ACP, conﬁrming
that its propensity toward phase transitions and exchange of
material with the medium is signiﬁcantly more pronounced
than that of HAp or DCP,
8Ca3(PO4)2  3H2Oþ Ca3(PO4)2 þ 8H2O
! 3Ca8H2(PO4)6  5H2Oþ 3Ca2þ þ 6OH, (6)
5Ca8H2(PO4)6  5H2Oþ 3H2O! 8Ca5(PO4)3OH
þ 6HPO42 þ 12Hþ, (7)
4Ca3(PO4)2  3H2Oþ Ca3(PO4)2
! 3Ca5(PO4)3OHþ HPO42 þ 2Hþ: (8)
To test if the release of protons is responsible for the
elicitation of the antibacterial effect, the activity of ACP
and DCP, the two proton-releasing CP phases analyzed
here, was tested in parallel. The activity of DCP not sub-
jected to the thermal treatment was higher than that of
ACP against E. coli in the high concentration range, but
signiﬁcantly lower against S. aureus and P. aeruginosa in
the entire range of concentrations (Fig. 6). The fact that
DCP acidiﬁes the medium most, but has a more viable
effect on S. aureus and P. aeruginosa than ACP refutes the
idea that the release of protons following the reprecipita-
tion of CP growth units that transiently separate, like a
comet tail, from the particle surface is solely responsible
for the antibacterial effect. The lack of effect of the local
pH drop caused by the surface dissolution and reprecipita-
tion is in agreement with the similar inability of polyesters
to elicit antimicrobial effects solely due to their mild
acidity.42 The idea that the release of protons cannot be the
decisive antibacterial factor per se is additionally sup-
ported by the fact that the activity of HAp, whose
proton-releasing capacity should be signiﬁcantly lower
than that of ACP, was absent against S. aureus, but compa-
rable and per some criteria, e.g., IC50, even higher than
that of ACP. Besides, carbonates and phosphates, along
with amino acid side chains and terminal groups capable
of undergoing protonation/deprotonation, should effec-
tively buffer the H+/OH− imbalance of this, relatively
minor degree and prevent their adverse effects on protein
structure and stability. One such buffering capacity of
tissues explains why alkalization achieved by relatively
soluble Ca(OH)2 is effective only against bacteria on open
surfaces, but not inside tissues, even when they are rela-
tively low in cellular count, such as dentin or the root
FIG. 6. Reduction in the concentration of colony forming units of S. aureus (a), E. coli (b), or P. aeruginosa (c) in broths treated with ACP or DCP nanoparti-
cles in the 0–100 mg/ml concentration range. Data points represent averages (n = 3) and error bars represent the standard deviation.
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canal, where the high pH produced by Ca(OH)2 is usually
buffered and kept in the physiological range.43
D. Particle size
It is widely known that particle size has a powerful effect
on biological properties, even more so when nanomaterials
are compared to their bulk analogues.44 Even within nano-
materials, ﬁne variations in the particle size can produce
humongous differences in the biological response to these
materials.45 As far as antimicrobial silver is concerned, the
sub-10-nm particles were reported to be more effective than
the bigger units.46 To test whether the particle size has an
effect on the antibacterial activity of CPs, the activity of
HAp and ACP powders against planktonic P. aeruginosa
was compared to the activity of their dry cements, which
were typiﬁed by different particle size histograms and
average particle sizes. Namely, while the particle size
distribution in HAp powders and dry cements was similar
[Fig. 7(a)], the average particle size was somewhat larger in
HAp powders than in cements [Fig. 7(c)]. In contrast, the
particle size in ACP powders was signiﬁcantly smaller than
in dry ACP cements [Figs. 7(b) and 7(c)]. Whereas in the
case of HAp, no phase transition accompanies the cement
formation process and the introduction of the liquid phase
and agitation manage merely to break down the ﬁne particle
agglomerates, crystallization parallels the cement formation
from the ACP precursor, resulting in grain coalescence and
growth. Planktonic P. aeruginosa was chosen for this assay
because of the relatively minor difference in the efﬁcacy of
ACP and HAp powders against it.1 Dispersed in the inocu-
lated broths, all powders signiﬁcantly reduced the bacterial
population growth, even at the lowest tested concentration of
10 mg/ml [Fig. 7(d)]. More importantly, however, the anti-
bacterial effect of ACP cement was consistently lower than
that of the corresponding powder and the effect was opposite
FIG. 7. Comparative particle size distribution histograms [(a) and (b)] and average particles sizes (c) for HAp [(a) and (c)] and ACP [(b) and (c)] powders and
dry cements, and the comparison of the concentration of P. aeruginosa colony forming units per ml of the bacterial broth treated with HAp powders or dry
cements at the concentrations of 10, 50, and 100 mg/ml. Data points represent averages (n = 3) and error bars represent standard error of the mean in (c) and
standard deviation in (d). Data points statistically signiﬁcantly lower (p < 0.05) compared to the control, untreated population are marked with an asterisk.
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for HAp. For both ACP and HAp, the solids containing
smaller particle sizes (ACP powder and HAp cement) exhib-
ited a more pronounced antibacterial effect than their ana-
logues containing larger particle sizes. With the average
particle size being on the nanoscale, i.e., <100 nm, for all the
systems, these ﬁndings indicate that the nanoparticulate
nature of CPs is an important prerequisite for their exhibition
of optimal antibacterial activities. Indirectly, the fact that
there was a difference in the treatment outcome depending
on the particle size reiterates the aforementioned point that
particles, not merely ions, must elicit properties that induce
the antibacterial effect. This reinforces our hope that materi-
als science can be used to craft therapies that equal or
surpass in effectiveness those of traditional antibiotics and
other molecular pharmacotherapies.
E. Crystallinity
Because of the lower interfacial energy, amorphous particles
are absorbed systemically faster than their crystalline counter-
parts.47 However, there is no model proposing a general differ-
ence between crystalline and amorphous modiﬁcations of
particles in terms of their biological effects at the cell level.
Still, prior research has shown that the amorphous phase of CP
exhibits an increased activity in cell culture compared to any
crystalline modiﬁcations.48 Also, as demonstrated by the clear
difference in the antibacterial activities of HAp and ACP
against particularly Gram-positive bacteria and by the selective
engagement of ACP or HAp into synergies with speciﬁc anti-
biotics, crystallinity has a deﬁnite effect on the antibacterial
properties of CPs.1 Only one effect is presented here, concern-
ing the selective engagement of only ACP, but not HAp, in
synergy with vancomycin against P. aeruginosa, activating
this antibiotic, which is otherwise ineffective against this bacte-
rium, and making it very effective in inhibiting the bacterial
growth. Thus, whereas the combination of vancomycin and
HAp does not lower the bacterial colony count in broths at all,
the combination of vancomycin and ACP reduces it by 80%
already at the very small ACP dose of 0.5 mg/ml (Fig. 8). For
each particle concentration tested in the 0.5–20mg/ml range,
there is a statistically signiﬁcant to extremely signiﬁcant differ-
ence in the effect of these two combination therapies (Fig. 8).
Crystallinity, however, presents mainly a bulk phenomenon
and only its effect on the surface processes, which come into
direct contact with the bacteria, is expected to be important.
Surface, of course, is deﬁned as the ﬁrst 10–20 atomic layers
and itself presents but a different kind of a bulk phenomenon.
As will be pointed out in further sections, crystallinity is not
simply proportional to the antibacterial activity; rather, the fact
that ACP is more effective against Gram-positive lab strains
and HAp against the multidrug-resistant (MDR) analogues
suggests that ACP and HAp must be typiﬁed by thoroughly
different mechanisms of action.
F. Structural metastability and surface defects
In the next stage of this study, we wanted to explore
whether UV light, in analogy to the effect it causes in
inorganic antibacterial materials with photocatalytic proper-
ties, such as titanium oxide and zinc oxide, can augment the
antibacterial activity of CPs and, thus, indirectly point at the
MoA involving the formation of radical oxides as the result
of optically active surface and bulk defects. To that end, the
optical properties of ACP and HAp were examined using
UV–Vis PL and diffuse reﬂectance (DR) spectroscopy. The
DR spectra displayed a similar adsorption edge, near
205 nm, for both ACP and HAp powders [Fig. 9(a)].
The absorption capacity of ACP in the short-wavelength UV
(UVC) region (100–280 nm) was higher than that of HAp,
especially at 205 nm where this capacity is almost four times
higher. The higher UVC light absorption capacity of ACP
may be attributed to its lower crystallinity compared to HAp.
In optically inactive or weakly active materials, crystallo-
graphic defects usually present the sites of a greater optical
activity compared to the points in a perfect lattice, the reason
being the conformational heterogeneity of the electronic
states around the defects, which causes the spread of the
absorption and emission energies and makes transitions for-
bidden in a perfect system practically possible.49 ACP and
HAp also had a similar reﬂectance in the visible light region,
ranging between 100% and 93.5%. Because the measure-
ments were performed on pellets with the thickness of 1 mm,
the transmission effects were neglected and the absorption
capacity was directly correlated with the reﬂectance. The
direct bandgap energies (Ebg) were determined from
Kubelka–Munk function versus photon energy (eV) plots
shown in Figs. 9(b) and 9(c) and Ebg values were the same,
225 eV, for both HAp and ACP. Luminescence photographs
taken under the excitation of 405 nm show the brighter, bluer
emission for HAp than for ACP [Figs. 9(d) and 9(e)]. This
blue photoluminescence, emitting without the presence of
FIG. 8. Broth concentration of colony forming units of P. aeruginosa treated
synergistically with different concentrations of ACP or HAp nanoparticles
and 100 mg/ml of vancomycin. Data points represent averages (n = 3) and
error bars represent the standard deviation. Different levels of statistically
signiﬁcantly difference between the concentration of colony forming units in
HAp- and ACP-treated broths are marked with * if signiﬁcant (p < 0.05), **
if highly signiﬁcant (p < 0.001), or *** if extremely signiﬁcant (p < 0.0001).
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activators, was detected before50,51 and has a biomedical
potential that extends beyond the scope of this study.52,53 PL
spectroscopy was used next to determine the type of defects
present in ACP and HAp. The room temperature PL spectra
are presented in Figs. 9(f ) and 9(g). Although the two CP
powders were sensitive to different excitation wavelengths in
the 320–400 nm region, both PL spectra displayed a wide
emission band in the visible, 390–600 nm range. This wide
emission band was the convolution of three blue emission
components centered near 440, 470, and 505 nm. These blue
emission bands were caused by the surface and bulk defects,
such as vacancies, structural defects, and lattice distortions.
The free radical formation process is assumed to involve
photo-induced formation of an electron vacancy on the parti-
cle surface and the electron transfer to a PO4
3− oxygen,
which is followed by the formation of a superoxide radical
(O2 )˙ capable of oxidizing adjacent biomolecules and react-
ing with water molecules to produce other radicals, including
hydroxyl radicals (OH )˙ and hydrogen peroxide (H2O2).
54
The higher PL intensity of HAp in comparison with that of
ACP was due to a larger crystallite size and crystallinity of
the former powder. The prerequisite for an efﬁcient photoca-
talytic activity, such that it leads to the generation of antibac-
terially active species, including OH ,˙ H2O2, and O2 ,˙ is that
the energy of the irradiation source lies within the bandgap
of the material.55 With the absorption by CP nanoparticles
lying within the UV region, it is conceivable that the simple
exposure to sunlight might be sufﬁcient to activate the mate-
rial. Namely, sunlight contains ∼5%–7% of UV rays, with
the rest being visible and infrared light, both present in
approximately equal amounts: 46%–48%.56
All in all, these data indicate that a considerable concen-
tration of defects is present on the surface and in the bulk of
CP nanoparticles and that they are able to be excited in the
presence of the UV radiation, endowing the particles with
luminescent properties. The question, however, was whether
these defects were capable of generating free radicals in
contact with the solution and, thus, be responsible for the
activity against bacteria. To answer this, a P. aeruginosa
broth assay was performed with concomitant UV irradiation
and the results are shown in Fig. 10. Interestingly, the reduc-
tion in the microbial population due to 5 min UV irradiation
was identical to that achieved by the IC50 dose of ACP nano-
particles in the absence of the UV treatment. Moreover, no
augmentation achieved by concomitant nanoparticle and UV
treatment compared to the treatment with nanoparticles alone
suggests that, though defect-generated radicals may be
present in the system, they do not constitute the main MoA
of these particles. This makes CP nanoparticles mechanisti-
cally different from photocatalysts such as the oxides of zinc,
tin, titanium, and, to some extent, magnesium.
G. Nanoparticle diffusion coefﬁcient
To test whether the diffusion of nanoparticles through the
medium beneﬁts their antibacterial activity, the activity of iden-
tical ACP powders was compared in broths and agar assays.
As seen from Figs. 11(a) and 11(b), while 5 mg/ml of ACP
powder signiﬁcantly decreased the activity of P. aeruginosa in
broths, the inhibition zones were not detected in the agar assay
around 5mg deposits of ACP powder, indicating a minimal
activity of ACP under these conditions. P. aeruginosa, the
FIG. 9. UV–Vis diffuse reﬂectance spectra of ACP and HAp (a). Kubelka–Munk curves from which the bandgap energies for ACP and HAp were determined
by extrapolation [(b) and (c)]. Luminescence photographs of ACP and HAp powders under 405 nm irradiation in the dark [(d) and (e)]. Photoluminescence
spectra of ACP and HAp under different excitations [(e) and (f )].
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specie selected for this assay, was not observed to form any
more bioﬁlm on agars than in broths, where the bioﬁlm amount
forming was considerable. Similar results were, however,
obtained for a nonbioﬁlm-forming species, E. coli. Agar assays
were also performed to compare the activity of ACP powders
and their corresponding viscous suspensions against P. aerugi-
nosa. As can be seen from Figs. 11(b) and 11(c), whereas ACP
powder displayed no inhibition zone around it, these zones
were pronounced against ACP gels. As viscous gels diffuse
into the infected agars more pronouncedly than the powders,
this difference in the effect between the two formulations sug-
gests that the activity of CPs is critically dependent on the
ability of the nanoparticles to diffuse to the bacterial cell as
opposed to acting as a static substrate that sits and waits for the
bacteria to bind to it. An earlier study showed a negligible anti-
bacterial effect of ACP nanoparticles with a similar size
(116 nm on average) as those utilized in this study, but brought
into contact with bacteria in the compact form, as composite
blocks.57 The fact that the antibacterial effect is present when
ACP nanoparticles are delivered as powders suggests that their
diffusion through the medium is one of the prerequisites for
FIG. 10. Broth concentration of colony forming units of P. aeruginosa aged
overnight after the 5 min treatment with the MIC50 (90 mg/ml) of ACP with
(ACP + UV) and without (ACP) the concomitant UV irradiation compared
to the broths treated with UV light alone (UV) and broths not subjected to
any treatment (control). Data points represent averages (n = 3) and error bars
represent the standard deviation. Data points statistically signiﬁcantly lower
(p < 0.05) compared to the control, untreated population are marked with an
asterisk.
FIG. 11. Reduction in the broth concentration of colony forming units of P. aeruginosa after the treatment with 5 mg/ml of ACP powder compared to the
untreated, negative control (a). No inhibition zone forming around 5 mg of ACP powder deposited on an agar plate inoculated with P. aeruginosa and distinct
zones of inhibition forming around rifampicin and rifampicin-loaded ACP (b). Moderate zones of inhibition forming around 5 mg of ACP cements deposited
on an agar plate inoculated with P. aeruginosa (c).
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their action. Since most clinical applications of CPs utilize it
as a static materials component, be it as bioactive coatings of
implants or to reinforce tissue engineering constructs, these
insights suggest that the beneﬁts of the diffusive form of the
same nanoparticles might be even greater, albeit being greatly
unexplored. These experiments are in agreement with the
higher activity of nanoparticles than that of the larger particu-
lates that was elaborated earlier in the text. However, they
also hint at the signiﬁcant role played in the process by even
ﬁner atomic clusters, which we cover in Sec. III H.
H. Ion/cluster exchange dynamics across the particle/
solution interface
CP particles exhibited the antibacterial effect in both the
pulverized and the cement form, with a clear difference in
the particle size between the two (Sec. III D). Although the
bacteria were consistently less viable when challenged with
the formulations containing lower particle sizes, the differ-
ence was statistically signiﬁcant only in one-third of all com-
parisons, and both formulations were capable of signiﬁcantly
inhibiting the bacterial growth [Fig. 7(c)]. This has suggested
that the nanosize of primary CP particles plays an important
role, but is not the major antibacterial factor.
CP particles are typiﬁed by an extraordinary phase compo-
sition volatility and dynamics at the interface with aqueous
solutions. The inherent instability of CP particles predisposes
them for a constant exchange of ions and ﬁne atomic units,
comparable in size to Ca9(PO4)6 hexagons aka Posner’s
clusters, across the solid/liquid interface, regardless of the par-
ticle size. The formation of HAp, for example, proceeds
through hierarchical aggregation of differently sized growth
units, with the ﬁnest of them being 9 Å sized Posner’s clusters.
Although this aggregation-based growth is usually associated
with biomimetic, surface-controlled precipitation,58,59 it is also
observed as the mechanism of growth in the absence of any
organic additives.60–62 In addition, an equilibrium state at the
solid/liquid interface implies a ﬁnite exchange of ions between
the two phases and this exchange is expected to be more
intense in HAp than in other oxides because of its intrinsically
hydroxylated nature. As a result, these clusters are expected to
constantly surround CP particles in contact with the aqueous
medium, even when preformed particles are dispersed in it.
Visualizing these ultraﬁne, transient entities would require the
stretching of the spatiotemporal resolution of state-of-the-art
aberration-corrected transmission electron microscopes beyond
their current limits and more indirect analytical techniques
must be resorted to. A couple of experiments based on these
techniques were designed to test the effect of the cluster
exchange dynamics across the particle/solution interface,
imaginable as the tail of a comet as it traverses the cosmic
space. In conceiving the ﬁrst experiment, we were guided by
the idea that ACP should create a higher concentration of
these units within the Stern layer and Debye length limits than
crystalline apatite.
The greater degree of exchange of content across the par-
ticle/solution interface in ACP compared to its crystalline
counterpart, HAp, was indirectly illustrated by a higher
release rate of three different molecules from ACP than from
HAp [Figs. 12(a)–12(c)]. These molecules included a large
protein, bovine serum albumin (BSA), and two small mole-
cules with almost identical molecular weights but with a
very different hydrophobicity: a model drug, ﬂuorescein
(log P = 3.2), and an antibiotic, ciproﬂoxacin (log P =−1.4).
Fluorescein was released faster than BSA and BSA was
released faster than ciproﬂoxacin, showing that the retention
of the compound on the particle surface is directly propor-
tional to the hydrophilicity of the compound. The release
efﬁciency measured on ACP and HAp for three different
antibiotics, including ampicillin, vancomycin, and erythro-
mycin, conﬁrmed that all three drugs, irrespective of their
chemical properties, adsorb on and desorb from ACP much
more efﬁciently than from HAp [Figs. 12(d)–12(f)], presum-
ably because of a greater degree of content exchange across
the particle/solution interface in ACP. These results also
demonstrate that small hydrophobic molecules (e.g., ﬂuores-
cein or ampicillin) adsorb on and desorb from highly convex
nanoparticle surfaces better than large hydrophilic molecules
(e.g., BSA or vancomycin). Hence, the amount of the drug
loaded onto the particles and released within 24 h when
normalized to the weight of the carrier was highest for
ampicillin (logP = 0.9, Mw = 349.4 g/mol), reaching 400%
for ACP, which was higher than 70% and 4.8% for vanco-
mycin (logP = −3.1, Mw = 1449.3 g/mol) and erythromycin
(logP = 3.1, Mw = 733.9 g/mol), respectively [Figs. 12(d)–12(f)].
The same trend was observed for HAp, with the most efﬁ-
ciently loaded and released drug being ampicillin (146%),
ahead of vancomycin (15.2%) and erythromycin (3.5%),
conﬁrming that large size is a greater hindrance to adsorption
onto CP nanoparticles than hydrophobicity. Since drugs are
loaded onto CP nanoparticles strictly via adsorption, the
release rate should be directly proportional to the ﬂuctuant
ﬂux of ions and clusters across the solid/liquid interface. The
greater lattice disorder, higher hydration, and lower enthalpy
allow for bond breaking at a lower energetic cost on the
surface of ACP, leading to a greater surface dynamics and,
consequently, faster desorption of molecules.
The idea that the entities alternately dissipating from and
reintegrating with the particle surface exhibit a critical effect
on the antibacterial activity of CP nanoparticles was also tied
to our rejection of the simple interfacial free energy argu-
ment. Namely, lower hydration on the surface of HAp and
its lower degree of entropic similarity with the medium
imply a higher interfacial free energy compared to ACP.
Given its higher interfacial free energy compared to ACP,
HAp would present the site of a greater attraction to proteins,
which it could potentially destabilize. However, although
HAp was indeed more toxic to MDR strains, this could not
explain that ACP was more toxic to Gram-positive lab
strains. Hence, we were prompted to search for the key to
explaining this selective activity in a greater structural and
stoichiometric instability and dissipative composition of
ACP, notwithstanding that HAp also must have a unique or
very pronounced structural feature that endows it with a
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potential to surpass the activity of ACP against certain bacte-
rial species.
Compared to its more stable compositional analogue, HAp,
we envisaged ACP as a nanoscopic comet leaving a greater
trail in a biological milieu, generating ﬁne clusters that may be
toxic to bacteria. These dynamic changes present at the parti-
cle/solution interface are enabled by the intensely hydrated
and diffusive apatitic surfaces in general,63,64 but should be
more intense for an amorphous state, which is by deﬁnition
metastable and prone to change toward more thermodynami-
cally stable states. If validated, this hypothesis could explain a
signiﬁcant amorphous content of biomineral in bone65 and tie
it not only to the remodeling process, but also to the provision
of an intrinsic prophylactic activity to bone against the bacte-
rial proliferation. One such model of antibacterial activity
would be conditioned by the validity of the assumption that
phase transitions from as-precipitated ACP to crystalline HAp
proceed at least partially through the dissolution/reprecipitation
mechanism. Many are reported physical effects indicating the
correctness of this mechanism, including the inhibition of the
growth of HAp from ACP after polymers were adsorbed onto
ACP surface,66 the preservation of ACP structure by inter-
spersing ACP particles inside a chitosan matrix,67 and the
increased rate of HAp nucleation and ACP→HAp transfor-
mation at a lower pH,68 when the dissolution of ACP is
increased. The idea about the disparity between the dynamics
of the unceasing transition between the solution and the
crystal on the surface of ACP and HAp is reﬂected in the con-
ditions under which these two solids form: while both ACP
and HAp initially form as amorphous phases,69 prolonged
metastability of ACP is ensured by the more dynamic condi-
tions of precipitation, involving abrupt mixing of reagents and
a rapid attainment of sufﬁciently high supersaturation levels,70
thus favoring spontaneous precipitation of constitutive ions.71
In contrast, the transition of as-precipitated ACP to HAp is
fostered at lower supersaturations and in processes involving
heterogeneous nucleation on organic and other hydrophilic
substrates.72
As the transformation of the powder into cement increases
the amorphous content in the material, this would increase
the cometlike tail that the particles create in their diffusion
wake. This effect would be partly due to the greater degree
of amorphousness in the wet cements, but also partly due to
the pasty, heavily hydrated and semiﬂuid character that the
material adopts in such a form. To that end, we compared
the antibacterial efﬁcacies of dry powders and wet, not dry
cements as in the earlier experiment [Fig. 7(c)] as well as the
efﬁcacies of dry and wet cements. The experiment compar-
ing wet versus dry cements, assuming that the former would
have a greater concentration of Posner’s clusters and other
ﬁne particulate units moving back and forth across the solid/
liquid interface, has shown that the wet cements signiﬁcantly
increase the antibacterial activity. Thus, whereas the treat-
ment of E. coli broths with 10 mg/ml of dried HAp cements
FIG. 12. Kinetic proﬁles for three different molecules—ﬂuorescein (a), bovine serum albumin (b), and ciproﬂoxacin (c)—released from HAp or ACP powders
[(a) and (b)] or gels (c). The amounts of three different antibiotics—ampicillin (d), vancomycin (e), and erythromycin (f )—loaded and released within 24 h
from ACP and HAp and normalized to the weight of ACP/HAp.
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decreased the bacterial colony count compared to the untreated
control, albeit not in a statistically signiﬁcant manner, the treat-
ment with wet HAp cements did so with a conﬁdent level of
statistical signiﬁcance [Fig. 13(a)]. In contrast, ACP cements
did not produce a difference in bacterial concentrations depend-
ing on whether they were delivered as wet or dried, presumably
because ACP per se contains a rich solid/liquid interface thanks
to its amorphous character, which becomes barely increasable
when the hydration of the material is changed. One such
change, expectedly, produces a more signiﬁcant effect in HAp,
a CP phase more deprived of this rich interface in its dry, crys-
talline state compared to ACP.
The second experiment involved aging fresh HAp precipi-
tates in the parent solution for various periods of time and
also subjecting half of the samples in each sample group to a
thermal treatment by bringing the suspensions to boil.
The premise was that both aging and heating should stabilize
the nanoparticle surface by increasing the crystalline order
and reducing hydration. The fact that the HAp precipitate
heated and aged for the longest period of time exhibited a
higher antibacterial activity than precipitates with an identi-
cal phase composition, but aged for shorter periods of time
and not heated [Fig. 13(b)] suggests that particle properties
becoming less prominent following such treatments are not
responsible for exhibiting the antibacterial effects. These
properties include those dependent not only on surface
defects but also on the dynamics of the interfacial processes
involving Posner’s clusters and ionic species alternately sep-
arating from and anchoring back to the particle surface, all of
which should decrease in abundance with the aging and
thermal treatments. This observation is corroborated by no
difference between P. aeruginosa populations in broths
treated with HAp/ACP powders, which are relatively impov-
erished in the content of Posner’s clusters, and broths treated
FIG. 13. Comparison in the reduction of the concentration of colony forming units in E. coli [(a), (b), and (d)] or P. aeruginosa (c) bacterial broths treated with
different concentrations of 10 mg/ml HAp or ACP nanoparticles delivered as wet or dried cements (a), HAp nanoparticles prepared with and without the
boiling step and involving different precipitate aging times in the solution (b), HAp or ACP nanoparticles delivered as powders or as wet cements (c), and ACP
nanoparticles either freshly precipitated or aged in the solution for 3 h (d). Data points represent averages (n = 3) and error bars represent the standard deviation.
Data points statistically signiﬁcantly lower (p < 0.05) compared to the control, untreated population are marked with an asterisk.
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with the comparative concentrations of the same particulates
delivered as wet cements, presumably relatively richer in the
content of Posner’s clusters [Fig. 13(c)]. Another conﬁrma-
tion of little to no effect of the cluster exchange dynamics
came from an experiment comparing the antibacterial activity
of fresh and aged ACP powders. ACP precipitate is expected
to solidify structurally as its aging time in the parent solution
is increased; however, the nonexistent difference between
E. coli colony count in broths challenged with fresh ACP
and in broths challenged with aged ACP [Fig. 13(d)] sup-
ports the idea that Posner’s clusters are not a signiﬁcant anti-
bacterial factor. That they may exert some effect, however,
can be concluded from the higher activity of the fresh and
Posner-cluster-enriched ACP than its aged counterpart at
40 mg/ml dose [Fig. 13(d)]. All of this suggests that these
clusters, alongside other transient species consequential to
the interfacial dynamics, do play some, but not the major
role in causing the antibacterial activity of CPs.
I. Particle morphology effects
For the sake of curiosity, the note on which science
should begin and end, we analyzed the effect of the sequence
of the addition of reagents during synthesis on antibacterial
properties of the powder product. Thus, we compared parti-
cles precipitated by introducing Ca2+ ions dropwise to a
phosphate-rich solution with the regular precipitates prepared
in the opposite manner, that is, by adding HxPO4
x–3 ions
dropwise to a calcium-rich solution. Variations in the
sequence of addition of reagents to a mixture have routinely
caused changes in materials properties, including particle
size and speciﬁc surface area, in turn, affecting their perfor-
mance.73 In our case, this variation produced no signiﬁcant
change in the particle size, but it caused a minor, but
detectable level of change in the particle morphology:
namely, HAp nanoparticles precipitated at low Ca/P ratios,
by adding Ca2+ ions to a phosphate-rich solution, had some-
what sharper edges [Fig. 14(b)] than HAp nanoparticles pre-
cipitated at high Ca/P ratios [Fig. 14(a)]. This difference is
expected in view of the fact that precipitation at a high con-
centration of the more chaotropic ion, in this Ca2+, is per-
formed when one wants to break the crystalline symmetry
and produce round morphologies. In contrast, precipitation at
a high concentration of the more kosmotropic ion, in this
PO4
3−, is performed when one wants to conduct crystal
growth in conformity with the crystalline symmetry of the
compound and produce more complex morphologies.
Biomimetic precipitation of apatite proceeds at a low Ca/P
molar ratio,74 presumably because the phosphate network
provides a heavier, kosmotropic ionic skeleton to be ﬁlled
with the lighter, more diffusive and chaotropic Ca2+ ions.
This precipitation results in elongated, plate-shaped morphol-
ogies75 that conform to the hexagonal space group of HAp
and is also in agreement with the more decisive effect of
anions on the microarchitecture of ﬁne particles76 and with
the order-breaking effect Ca2+ ions impose on many biologi-
cal structures.77 Also, it should be noted that even in the
absence of an evident change in particle properties due to a
variation of the sequence of the addition of reactants to the
mixture, a change in the surface composition and double
layer dynamics caused by this procedural variation could
have a powerful inﬂuence on the particle/cell interaction.
The difference in the antibacterial activity depending on
the sequence of reagent addition was noticeable and very
pronounced against E. coli, in which case the HAp powder
prepared at low Ca/P ratios was more effective than the
powder prepared at high Ca/P ratios at all three tested
FIG. 14. SEM images of HAp nanoparticles synthesized by the addition of an NH4H2PO4 solution into a Ca(NO3)2 solution (P→Ca) (a) or by the addition of
a Ca(NO3)2 solution into an NH4H2PO4 solution (Ca→ P) (b). Viability reduction of different bacterial populations, including E. coli, P. aeruginosa, and
S. aureus, in response to the treatment of HAp nanoparticles in doses of 0, 40, 60, and 80 mg/ml depending on whether they were formed by introducing an
NH4H2PO4 solution into a Ca(NO3)2 solution (P→Ca) or vice versa (Ca→ P) (c). Data points represent averages (n = 3) and error bars represent the standard
deviation. Data points statistically signiﬁcantly different (p < 0.05) with respect to the comparative data point are marked with an asterisk.
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concentrations. A signiﬁcant difference between the activities
of the two powders against P. aeruginosa was present only
at the lowest of the three particle concentrations tested and in
that case, the opposite effect from that observed in E. coli
was at work [Fig. 14(c)]. Similarly, the activity of the
powder prepared at high Ca/P ratios was higher in S. aureus,
albeit only at the highest concentration in a signiﬁcant manner
[Fig. 14(c)]. The fact that the antibacterial effect against
E. coli was more pronounced for the somewhat sharper parti-
cles of HAp precipitated at low Ca/P ratios—that is, when
Ca2+ was added to HxPO4
x–3 rather than vice versa—may
suggest that elongated and other anisotropic particle morpholo-
gies may be often, but not always, more toxic to the cells than
their rounder counterparts. This insight would be drawn in
analogy to the shape effect observed in calciﬁed deposits in
atherosclerotic plaque,78 asbestos in lung disease,79 and ﬁla-
mentous bacteria that are less efﬁciently phagocytosed than
bacilli or cocci.80 Our previous study demonstrated that
rounder CP particle morphologies translate to a greater antimi-
crobial potency, but only when sizes of these particles are
lower than those of their plate- and needle-shaped analogues.81
As we show here, if the particle size remains unchanged, parti-
cles with sharper edges may be deadlier to some bacteria than
their rounder counterparts. Also, with the antibacterial effect
against E. coli being more intense for the powder prepared at
low Ca/P ratios, this may indirectly reiterate the abovemen-
tioned point that diffusive ionic units on the particle/solution
interface, which should be more concentrated in this material,
are a factor deﬁning the antibacterial activity of these CPs.
Overall, experiments involving a variation to the reagent addi-
tion sequence illustrates a ﬁne point, which is that the antibac-
terial activity of CPs can be controlled and optimized within a
broad window of values by relatively simple means. It brings
hope that with a sufﬁcient input of materials chemistry knowl-
edge, the antibacterial activity of CPs could be made competi-
tive with the more popular and applied inorganic alternatives.
This hope will be the driver of the future optimization studies.
IV. CONCLUSION
In the ﬁrst part of this study,1 we evidenced and elaborated
on a deﬁnite antibacterial effect of two different CPs, namely,
HAp and ACP, both alone and in synergy with antibiotics.
A number of antibiotics ineffective against particular bacterial
species were suddenly rendered effective when they were
codelivered with CP nanoparticles. There was also a selective
effect depending on the crystallinity of CPs, with the most
drastic example being that of Gram-positive species, against
which ACP was active and HAp was not. Also, while HAp
was ineffective against regular Gram-positive species, it
proved effective against their MDR analogues. In this, second
part of the study, we engaged in the quest for a key CP nano-
particle property responsible for eliciting these curious effects.
A number of material properties were subjected to system-
atic scrutiny and some of them were discarded as nonessen-
tial for explaining the antibacterial effect, thus putting an
end to frequently erred hypotheses in the literature. For
example, while both HAp and ACP displayed blue emission
bands owing to crystallographic defects, these defects were
incapable of generating reactive oxygen species under exci-
tation in concentrations sufﬁcient to induce bacteriostasis
and it was concluded that CPs do not share the photocata-
lytic MoA with materials such as ZnO or TiO2.
A few properties of CP particles stood out as having a
deﬁnite, albeit not decisive effect on their antibacterial activ-
ity. These effects are graphically depicted in Fig. 15. First,
the nanosized nature of the particles is highlighted because it
presented a prerequisite for their exhibition of the antibacte-
rial mode of action. Second, the ability of the nanoparticles
to move through the medium and diffuse their way to the
cell was essential too. The zwitterionic nature of the nano-
particle surface and its globally negative charge, albeit rela-
tively low in magnitude, was hypothesized to have played a
role in minimizing the electrostatic repulsion barrier between
the nanoparticle and the cell and facilitating their coming
into contact with one another, if not providing the electro-
static attraction to cationic residues of the peptidoglycans
and polysaccharides covering the surface of Gram-positive
and Gram-negative bacteria, respectively. Finally, there was
the beneﬁt of the particles’ rich interface exchange dynam-
ics, through which they form a cometlike tail by continu-
ously dissipating and reintegrating their content in the form
of ﬁne atomic clusters as they move through the liquid
FIG. 15. Scheme describing key particle properties acting as determinants of the antibacterial activity of CP nanoparticles in interaction with bacterial cells,
including (a) nanoscopic size; (b) release of calcium ions and elevation of the intracellular concentration of calcium; (c) diffusivity and low globally negative
charge of a zwitterionic surface that minimizes the electrostatic barrier posed before the nanoparticle approaching the bacterial cell; and (d) Posner’s and simi-
larly sized atomic clusters creating a rich and dynamic hydrodynamic environment surrounding the diffusive nanoparticles, analogous to the tail of a comet,
constantly dissipating and reintegrating with the particle surface, the drawing of the limits of which is challenging because of the complexity of this interface.
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medium. Coming into contact with the peptidoglycans of the
cell wall, these ﬁne clusters do not redeposit on the CP parti-
cle surface, effectively in a constant state of recrystallization,
but are able to interfere with and disrupt the structure of
these biological entities. A portion of this ionic trail perma-
nently leaves the particles and may affect the bacteria if
exceeding particular thresholds, which brings us to the
fourth effect, namely, bacteria challenged with CP nanoparti-
cles contained twice more intracellular Ca2+ ions than the
control bacteria. Most of these numbered effects are affected
by crystallinity, thus explaining the fundamental disparity
between the effect of ACP and HAp on Gram-positive
species. None of these effects, however, was of such a criti-
cal magnitude that it could be a major or sole determinant of
the antibacterial activity. Also, given that there are multiple
properties of importance, it would be erroneous to exclude
the effects of properties that had no effect in the assays we
designed here because they might be just as well tying the
aforementioned properties together. Generation of nanopockets
rich in protons upon reprecipitation of surface units dissipated
in action and the hydrodynamic cloud enriched in Ca2+ ions
surrounding the particle as the result of this alternate dissolu-
tion and crystallization may be such phenomena that alone
have no effect on the bacteria, but are essential components of
a complex synergy of factors. One of these inactive factors
might be crucial in facilitating the transport of active factors to
the site of action. For example, even if Ca2+ ions generated by
the dissolution of the ﬁne CP clusters forming due to the dis-
solution/recrystallization processes going on continuously on
the particle surface may not be capable of distorting the native
structure and function of the biomolecules that they come in
contact with and induce downstream effects causative of
necrosis and other toxic responses in the host cells, they may
still act as Trojan horses opening up porins, pumps, or ion
channels and enabling the intracellular passage of the nanopar-
ticles. As it frequently happens, in search of an answer to a
question, we have come across ever more complex questions.
Explaining this intricate synergy presents an enigma that con-
ﬁrms the age-old adage, according to which “every answer
asks a more beautiful question.”82 The failed quest for a holy
grail, a philosopher’s stone that a single key parameter repre-
sents may be disappointing to some, but not to anyone famil-
iar with the complex machinery called life where operations
proceed along redundant feedback loops that distribute the reg-
ulatory role over multiple nodes of the network and ensure
that the failure of any single one of them does not affect the
workings of the whole.
The synergistic effect of multiple particle properties,
emerging from the partial effect found in a number of
hypothesized mechanisms, is in agreement with the general
nature of inorganic antibacterial materials, including their
role model, silver.83 This multifaceted mechanism is also a
natural corollary of the pleiotropic nature of CPs. On the pos-
itive note, to this mechanistic pleiotropy and nonspeciﬁcity
CP nanoparticles owe their lesser potential to cause resis-
tance to therapy typical of narrow-range target-speciﬁc
molecular antibiotics. On a fundamentally problematic side,
the fact that a synergy of multiple factors is responsible for
causing the antibacterial effect implies an extraordinary difﬁ-
culty of elucidating the MoA, the fate of which may be
common to ceramic materials in general. On yet another,
more practically problematic side, this synergetic combina-
tion of causes of the antibacterial activity of CPs makes the
rational design of theirs for this type of medical application
difﬁcult, but not impossible. If synergetic, the exploration of
the MoA is inevitably multifactorial and may take an inﬁnite
number of possible angles, depending on their combinations
and contexts in which the studies would be conducted.
Hence, the search is far from over. Even now when the key
particle properties are delineated, a long and tortuous path
leads through particle design and property optimization in
search of clinically relevant efﬁcacies. If it took 14 years
from the discovery of penicillin for its structure to be deter-
mined, 16 for its mass production method to be reported
and 29 for it to be chemically synthesized, nothing short of
an equally winding path from the bench to the bedside can
be expected in this case too. In the end, we hope that the
versatile, pleiotropic nature of CPs complies with this multi-
faceted mechanism and will be advantageous in the long
run, not only because the microbiome transitioning endoge-
nously from the opportunistic to the pathogenic is polymi-
crobial by nature, but also because this intrinsic versatility
and tunability can be the gateway to the sphere of personal-
ized medicine toward which the most advanced biomaterial
therapies stream.
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